Commercial Celiac Disease Test to Hit European Markets |
X You may need to Reload the page to make it work correctly.

Commercial Celiac Disease Test to Hit European Markets

Diagnostic and pharmaceutical companies sign distribution agreement for point-of-care celiac disease test.

Augurix Diagnostics and Tillotts Pharma have entered into a commercialization agreement for Simtomax - a point-of-care test for screening celiac disease. The agreement grants Tillotts the exclusive right to distribute and supply Simtomax in dedicated key European markets.

The pocket-sized medical device will allow healthcare professionals, pharmacies and retail clinics to test patients for celiac disease and get immediate results. With a drop of blood, Simtomax can test for:

  • Immunoglobulin-A (IgA) anti-deamidated gliadin peptide
  • Immunoglobulin-G (IgG) anti-deamidated gliadin peptide
  • Total IgA level

The test is intended to be a first step in the diagnosis of celiac disease. Augurix recommends that a diagnosis be confirmed through intestinal biopsy.

While the announcement noted that Tillotts will be targeting European markets, it did not indicate any plans to bring the test to the U.S.

For more information, see the press release.


Advertise with us

  • Gluten Detective
  • Boar's Head 2019
  • 2019 Symposium
  • Gluten-Free Resource Directory
  • Look for the Beyond Celiac logo and shop gluten-free with confidence.


Complete our Celiac Disease Symptoms Checklist today to find out if you could have celiac disease and how to talk to your doctor about getting tested.